|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2007-10-8
|
|
pubmed:abstractText |
FR264205 is a novel parenteral 3'-aminopyrazolium cephalosporin. Here, we compared the stability of FR264205 against AmpC beta-lactamase of Pseudomonas aeruginosa with that of ceftazidime. The effect of ampD inactivation, which causes a moderate degree of hyperinducible AmpC expression, on the minimum inhibitory concentration (MIC) of FR264205 was eight-fold less than that on the MIC of ceftazidime. Hydrolysis efficiency (k(cat)/K(m)) towards FR264205 was substantially lower than that towards ceftazidime owing to a 20-fold-higher K(m) value. These results indicate that FR264205 is more stable against AmpC beta-lactamase than ceftazidime because of its low affinity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0924-8579
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
443-5
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Stability of FR264205 against AmpC beta-lactamase of Pseudomonas aeruginosa.
|
|
pubmed:affiliation |
Pharmacology Research Laboratories, Astellas Pharma Inc., 1-6, Kashima 2-chome, Yodogawa-ku, Osaka 532-8514, Japan. shinobu.takeda@jp.astellas.com
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
